Authors: Carhart-Harris RL¹², Williams TM², Sessa B², Tyacke RJ¹², Rich AS², Feilding A³, Nutt DJ¹²
¹ Imperial College London, Dept of Neuropsychopharmacology
² University of Bristol, Psychopharmacology Unit
³ The Beckley Foundation
²Corresponding author: email@example.com
This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the viability of functional magnetic resonance imaging work with psilocybin.